← Who reports today · Health Care
How Johnson & Johnson (JNJ) makes money: Q3 2026 revenue breakdown
Net earnings
$210M
down 95.9% y/y
Sales to customers
$25,399M
up 5.9% y/y
Operating Income (calculated)
$5,845M
down 16.9% y/y
Next report
~ Jan 20
not announced yet
The quarter in brief
Sales rose 5.9% y/y to $25.4B, but net earnings fell 95.9% to $210M ($0.09 per diluted share vs $2.12).
Key growth driver: Innovative Medicine — the fastest-growing revenue line: $16,757, +8% y/y. · by the Q3 2026 report
How does Johnson & Johnson make money?
Johnson & Johnson brought in $25.4 billion of revenue in Q3 2026, up 5.9% year over year. The largest source was Innovative Medicine: $16.8 billion, or 66% of the total, followed by MedTech ($8.64B, 34%). Net income for the quarter was $210 million, down 95.9% year over year.
Revenue by source, Q3 2026
- Innovative Medicine$16.8B · 66% · +7.7%
- MedTech$8.64B · 34% · +2.5%
Shares of $25.4B total revenue; changes are year over year, as reported. ≈ marks lines derived from disclosed totals. The same flows are drawn in the Sankey chart below.
All figures in $M.
| Line item | Amount and change |
|---|---|
| Innovative Medicine | $16,757 · +7.7% |
| MedTech | $8,642 · +2.5% |
| Sales to customers | $25,399 · +5.9% |
| Cost of products sold | $8,097 · +10.9% |
| Gross Profit | $17,302 · +3.7% · 68.1% margin |
| Selling, marketing and administrative expenses | $6,285 · +6.1% |
| Research and development expense | $4,652 · +26.7% |
| In-process research and development impairments | $339 · vs $0 |
| Restructuring | $181 · +187% |
| Operating Income (calculated) | $5,845 · −16.9% · 23.0% margin |
| Interest (income) expense, net | $31 · +72.2% |
| Other (income) expense, net | $5,780 · vs $478 |
| Earnings before provision for taxes on income | $34 · −99.5% |
| Income Tax Benefit | $176 |
| Net earnings | $210 · −95.9% · $0.09/sh · 0.8% margin |
Verdict: Sales rose 5.9% y/y to $25.4B, but net earnings fell 95.9% to $210M ($0.09 per diluted share vs $2.12).
The new supply chain restructuring program is expected to cost $650–750M through fiscal 2029.
Source and notation
Source: Johnson & Johnson press release, 8-K EX-99.1/99.2 of 10/13/2026 (SEC EDGAR). Operating income is calculated (gross profit minus SG&A, R&D, IPR&D impairments and restructuring) — the release does not print it; segment sales — from the release's segment table.
Open as an image: Johnson & Johnson (JNJ), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “Johnson & Johnson (JNJ) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/jnj. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/jnj"><img src="https://whoreportstoday.com/t/jnj/img/johnson-and-johnson-jnj-earnings-sankey.png" alt="Johnson & Johnson (JNJ) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/jnj">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/jnj/img/johnson-and-johnson-jnj-earnings-sankey.png
<a href="https://whoreportstoday.com/t/jnj">Johnson & Johnson (JNJ) Q3 2026 earnings chart (Who Reports Today)</a>
The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Other (income) expense, net swung to a $5,780M expense from $478M of income a year ago.
- R&D expense rose 26.7% to $4,652M (18.3% of sales vs 15.3%), plus $339M of IPR&D impairments.
- Gross margin narrowed to 68.1% from 69.6%.
- A $176M tax benefit produced an effective tax rate of (517.6)% vs 31.2% a year ago.
- Adjusted EPS, a non-GAAP measure, was $2.59 vs $2.80, on 2,448.6M diluted shares vs 2,428.6M.
What distorts the picture in this report and what to watch beyond the headlines.
Who runs the company now
As of 11/18/2026, per the company’s SEC filings: signatures on the latest report and leadership-change filings.
Positions and previous jobs: the company’s SEC filings. Spotted an error, or is this you and you’d like it corrected or removed? Contact us
Where they worked before
- Johnson & Johnsonsince 2016
- Chairman of the Boardsince 2023
- Chief Executive Officer and Directorsince 2022
- Executive Vice President, Worldwide Chairman, Pharmaceuticals2016
- Janssen-Farmaceutica1989Executive positions
Source: SEC EDGAR: 10-K annual report, 2026-02-11 · as of 10/21/2026
How this is compiled
Who runs the company now comes from primary sources only: for US and Canadian companies, the CEO and CFO signatures on the latest SEC report, and a separate board chair from the proxy materials; for Russian and Kazakh issuers, the company website and its disclosures. We recheck weekly; if a name can’t be confirmed, or a leadership-change filing came out after the report, we don’t show it until it’s reviewed. Previous jobs are only what the company itself disclosed about its current leaders (the past five years of business experience in the annual report and proxy materials): employer, position and years, restated as facts, with no age, education or other personal details. If the company doesn’t disclose it, we don’t look elsewhere. Anything more than 400 days past its last check is hidden. These are public business facts from disclosures, shown to tell investors who runs the company (our legitimate interest); if this is you and you object, contact us via the link above and we’ll remove it.
Sources · 2
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
- SEC EDGAR: 10-Q 2026-10-21 · SEC EDGAR · 11/18/2026
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged
The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global. Market share (US pharma & biotech): ≈13% by TTM revenue.
Heads-up
- net income fell 96% y/y in Q3 2026
Net income for Q3 2026: $210M, −96% y/y. In the report's figures: costs grew faster than revenue: research and development expense +27% y/y, restructuring +187% y/y, interest (income) expense, net +72% y/y. Based on the Q3 2026 report.
The company's report ↗Company reports
Company guidance
| Period | Company guidance | A year ago | Implied growth |
|---|---|---|---|
| FY2026 | revenue $101–101.4B (raised)EPS (non-GAAP) $11.05–11.15 (raised) | revenue $94.2BEPS (GAAP) $11.03 | revenue +7…8% |
Same quarter a year ago (ended December 28, 2025): revenue $24.56B, EPS (GAAP) $2.08
How we calculate
Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +7%).
EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.
Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.
Guidance comes from the company's earnings release (Form 8-K filed Oct 13, 2026); every figure is checked against the release text.
JNJ earnings history: past report dates
| Oct 13, 2026 Tue | 8:12 ambefore market open | Sep 27, 2026 | $25.4B+6% y/y | $0.09−96% y/y |
| Jul 15, 2026 Wed | 7:49 ambefore market open | Jun 28, 2026 | $25.3B+7% y/y | $2.27−1% y/y |
| Apr 14, 2026 Tue | 7:35 ambefore market open | Mar 29, 2026 | $24.1B+10% y/y | $2.14−53% y/y |
| Jan 21, 2026 Wed | 7:46 ambefore market open | Dec 28, 2025 | ≈$24.6B+9% y/y | ≈$2.08+48% y/y |
| Oct 14, 2025 Tue | 7:22 ambefore market open | Sep 28, 2025 | $24.0B+7% y/y | $2.12+91% y/y |
| Jul 16, 2025 Wed | 8:06 ambefore market open | Jun 29, 2025 | $23.7B+6% y/y | $2.29+19% y/y |
| Apr 15, 2025 Tue | 8:14 ambefore market open | Mar 30, 2025 | $21.9B+2% y/y | $4.54+239% y/y |
| Jan 22, 2025 Wed | 6:35 ambefore market open | Dec 29, 2024 | ≈$22.5B+5% y/y | ≈$1.41−16% y/y |
| Oct 15, 2024 Tue | 7:37 ambefore market open | Sep 29, 2024 | $22.5B+5% y/y | $1.11−89% y/y |
| Jul 17, 2024 Wed | 8:14 ambefore market open | Jun 30, 2024 | $22.4B+4% y/y | $1.93−2% y/y |
| Apr 16, 2024 Tue | 7:06 ambefore market open | Mar 31, 2024 | $21.4B+2% y/y | $1.34 |
| Jan 23, 2024 Tue | 7:45 ambefore market open | Dec 31, 2023 | $21.4B+7% y/y | $1.67+26% y/y |
| Oct 17, 2023 Tue | 7:33 ambefore market open | Oct 1, 2023 | $21.4B+7% y/y | $10.21+508% y/y |
| Jul 20, 2023 Thu | 7:15 ambefore market open | Jul 2, 2023 | $21.5B+6% y/y | $1.96+9% y/y |
Show all 14 reports since 2023Show fewer
How we count
Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.
Johnson & Johnson: 15-year financials
| 2025 | 94,193 | — | 26,804 | 19,698 |
| 2024 | 88,821 | — | 14,066 | 19,842 |
| 2023 | 85,159 | — | 35,153 | 18,248 |
| 2022 | 79,990 | — | 17,941 | 17,185 |
| 2021 | 78,740 | — | 20,878 | 19,758 |
| 2020 | 82,584 | — | 14,714 | 20,189 |
| 2019 | 82,059 | — | 15,119 | 19,918 |
| 2018 | 81,581 | — | 15,297 | 18,531 |
| 2017 | 76,450 | — | 1,300 | 17,777 |
| 2016 | 71,890 | — | 16,540 | 15,541 |
| 2015 | 70,074 | — | 15,409 | 16,106 |
| 2014 | 74,331 | 21,590 | 16,323 | 14,996 |
| 2013 | 71,312 | 16,412 | 13,831 | 13,819 |
| 2012 | 67,224 | 14,955 | 10,853 | 12,462 |
| 2011 | 65,030 | 13,765 | 9,672 | 11,405 |
$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.
How we calculate
Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.
Johnson & Johnson: 15-year balance sheet
| Year | Assets | Equity | Debt | Cash | Current assets | Current liabilities |
|---|---|---|---|---|---|---|
| 2025 | 199,210 | 81,544 | 49,933 | 19,709 | 55,624 | 54,126 |
| 2024 | 180,104 | 71,490 | 38,383 | 24,105 | 55,893 | 50,321 |
| 2023 | 167,558 | 68,774 | 30,801 | 21,859 | 53,495 | 46,282 |
| 2022 | 187,378 | 76,804 | 41,193 | 12,889 | 55,294 | 55,802 |
| 2021 | 182,018 | 74,023 | 35,882 | 14,487 | 60,979 | 45,226 |
| 2020 | 174,894 | 63,278 | 37,065 | 13,985 | 51,237 | 42,493 |
| 2019 | 157,728 | 59,471 | 28,896 | 17,305 | 45,274 | 35,964 |
| 2018 | 152,954 | 59,752 | 33,080 | 18,107 | 46,033 | 31,230 |
| 2017 | 157,303 | 60,160 | 36,081 | 17,824 | 43,088 | 30,537 |
| 2016 | 141,208 | 70,418 | 28,826 | 18,972 | 65,032 | 26,287 |
| 2015 | 133,411 | 71,150 | 26,861 | 13,732 | 60,210 | 27,747 |
| 2014 | 130,358 | 69,752 | 22,360 | 14,523 | 55,744 | 25,031 |
| 2013 | 132,683 | 74,053 | 23,080 | 20,927 | 56,407 | 25,675 |
| 2012 | 121,347 | 64,826 | 20,865 | 14,911 | 46,116 | 24,262 |
| 2011 | 113,644 | 57,080 | 26,327 | 24,542 | 54,316 | 22,811 |
$ millions, at fiscal year-end*.
* Sources
How we calculate
Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .
Cash flow
9 months ended 2026-09-27 · $M
| Line | This period | Year ago | Δ |
|---|---|---|---|
| Operating cash flowcash the business generated | 18,850 | 17,221 | +1,629 |
| · incl. D&A (non-cash add-back)depreciation & amortization | 6,080 | 5,492 | |
| · incl. stock-based comp (non-cash)share-based compensation | 1,115 | 1,045 | |
| Capexpurchases of property & equipment | −3,732 | −2,995 | −737 |
| Free cash flow ≈operating cash flow − capex | 15,118 | 14,226 | +892 |
| Investing activities, netcapex, acquisitions, securities | −4,859 | −19,103 | +14,244 |
| · incl. acquisitionsbusinesses net of cash acquired | −352 | −14,459 | +14,107 |
| Financing activities, netdebt, buybacks, dividends | −16,780 | −4,170 | −12,610 |
| · incl. buybacksrepurchases of common stock | −5,958 | −4,029 | −1,929 |
| · incl. dividends paid | −9,585 | −9,250 | −335 |
| FX effect on cash | −10 | 178 | −188 |
| Net change in cash | −2,799 | −5,874 | +3,075 |
How to read the table
Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.
Shareholders’ equity at Sep 27, 2026: $81.5B (41% of total assets). Compare with other S&P 500 companies →
Corporate governance
2/2good
- Jul 2026Per the Q2 2026 10-Q, the shareholder suit over talc risk disclosure is unresolved: a class has been certified, the Supreme Court denied review in April 2026, and expert discovery is under way. sec.gov ↗
- Dec 2025Dividend per share: $3.98 (2020), $4.45 (2022), $5.14 (2025) — raised every year (XBRL 10-K). data.sec.gov ↗
1 more fact and scoring
How the company treats minority shareholders: 2 — well, 0 — systematically poorly.
- Feb 2026Per the 2025 10-K, one class of shares; diluted share count −9.0% over 5 years (XBRL). sec.gov ↗
Scoring: 2.0, no deductions = 2.0
- Share classes
- Single class of common stock (10-K cover).
- Dilution
- Diluted share count −9.0% over 5 years (including the 2023 Kenvue exchange offer at a 7% discount in participants' favor); SBC 1.4%.
- Disclosure
- 10-Ks and 10-Qs filed on time, audited US GAAP financials; no deduction.
- Dividends
- Dividend raised for 60+ consecutive years: $3.98 (2020) → $5.14 (2025).
- Lawsuits & regulators
- 2018 shareholder class action over concealment of asbestos in talc: class certified, Supreme Court denied review (April 2026), now in the expert stage — unresolved, no deduction under the methodology; talc and opioid suits are product-related.
- Related parties
- No non-arm's-length related-party transactions; the Kenvue exit was done via an exchange offer at a discount in shareholders' favor.
How the score works · checked as of Oct 2026
Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap
Johnson & Johnson (JNJ) earnings: FAQ
How does Johnson & Johnson make money?
Johnson & Johnson brought in $25.4 billion of revenue in Q3 2026, up 5.9% year over year. The largest source was Innovative Medicine: $16.8 billion, or 66% of the total, followed by MedTech ($8.64B, 34%). Net income for the quarter was $210 million, down 95.9% year over year.
When is JNJ's next earnings date?
We have not yet seen an announcement of the date from Johnson & Johnson (JNJ). Based on last year's report on Jan 21, 2026, the next report is expected around Jan 20, 2027.
What time does JNJ report earnings?
Johnson & Johnson usually reports before market open: its latest results release was filed with the SEC at 8:12 am ET on Oct 13, 2026.
When did JNJ last report earnings?
Johnson & Johnson reported Q3 2026 results on Oct 13, 2026.
What has Johnson & Johnson guided for FY2026?
Company guidance for FY2026: revenue $101–101.4B (raised); EPS (non-GAAP) $11.05–11.15 (raised). A year ago (FY2025): revenue $94.2B, EPS (GAAP) $11.03. Implied growth: revenue +7…8%. Source: the company's earnings release (Form 8-K filed Oct 13, 2026).
Where can I find Johnson & Johnson's financial statements?
On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to JNJ's filings; this page breaks the latest report down in a Sankey chart.
What was JNJ's net income in Q3 2026?
Johnson & Johnson reported net income of $210M for Q3 2026 (−95.9% year over year), under US GAAP.
How has Johnson & Johnson's revenue changed since 2011?
Per its 10-K filings, revenue grew 1.4x: $65,030M in 2011 and $94,193M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.
New to earnings reports? Start with how to read an earnings report.
Get it every Monday: who reports this week
Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.
More reports: LH · Q3 2026 · LLY · Q3 2026 · MCK · Q1 FY2027 · MDT · Q1 2027 · MRK · Q3 2026 · MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · all reports